Similarly, reduction in the levels of circulating Tregs in HCC patients receiving systemic therapy, was associated with better treatment and disease outcomes due to reinvigoration of antitumor CD8+ T cell responses49. The gene discussed is CD8A; the disease is hepatocellular carcinoma.